Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by MaaT Pharma
< Previous
1
2
Next >
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
July 02, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
June 25, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
June 24, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
May 07, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
April 15, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
April 08, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale
April 05, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
March 28, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer
March 21, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies
March 19, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference
March 12, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma
March 05, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
February 29, 2024
From
MaaT Pharma
Via
Business Wire
MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations
December 12, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023
December 11, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan
November 30, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
November 09, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
November 06, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference
November 02, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies
October 31, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
October 26, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update
September 26, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
September 12, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation
September 07, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
July 27, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD
July 26, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
July 20, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces New Appointments to the Board and Executive Team
June 21, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
May 09, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
April 24, 2023
From
MaaT Pharma
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.